Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHAROAH: Pegcetacoplan Add-on in PNH
NCT02264639Phase 1Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Oct 2018
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH) (4 cohorts), sponsored by Apellis Pharmaceuticals. Primary endpoints: Number of Subjects With Treatment-Emergent Adverse Events During Single-dose Phase, Number of Subjects With Treatment-Emergent Adverse Events During Multiple-dose Phase up to 759 days and 2 more. Started Feb 2015; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02264639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264639.